Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

MARK ONE

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the Quarterly Period ended March 31, 2024; or

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from ________ to ________

Commission File Number: 000-55403

APPYEA, Inc.

(Exact name of registrant as specified in its charter)

Nevada

46-1496846

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

16 Natan Alterman St, Gan Yavne, Israel
(Address of principal executive offices)		Zip Code

(800) 674-3561

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 20, 2024, there were outstanding 451,113,064 shares of the registrant’s common stock, par value $0.0001 per share.

APPYEA, INC.

Form 10-Q

March 31, 2024

	Page

PART I — FINANCIAL INFORMATION

Item 1 – Unaudited Condensed Consolidated Financial Statements	4

Condensed Consolidated Balance Sheets – March 31, 2024 (unaudited) and December 31, 2022	5

Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 (unaudited)	6

Condensed Consolidated Statement of Changes in Stockholders’ Equity (deficit) for the three months ended March 31, 2024 and 2023 (unaudited)	7

Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 (unaudited)	8

Notes to Unaudited Condensed Consolidated Financial Statements	9-16

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3 – Quantitative and Qualitative Disclosures About Market Risk	23

Item 4 – Controls and Procedures	23

PART II — OTHER INFORMATION	24

Item 1 – Legal Proceedings	24

Item 1A – Risk Factors	25

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3 – Defaults upon Senior Securities	25

Item 4 – Mine Safety Disclosures	25

Item 5 – Other Information	25

Item 6 – Exhibits	25

Exhibit Index	25

SIGNATURES	26

APPYEA INC. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2024

APPYEA INC. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2024

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	Page

Condensed Consolidated Balance Sheets	5

Condensed Consolidated Statements of Operations	6

Condensed Consolidated Statements of Changes in Deficiency	7

Condensed Consolidated Statements of Cash Flows	8

Notes to the Condensed Consolidated Financial Statements	9-16

APPYEA INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in thousands)

	March 31, 2024			December 31, 2023
	Unaudited			Audited
ASSETS
Current assets
Cash and cash equivalents		373			222
Accounts receivables		1			-
Other accounts receivables		30			42
Inventory		14			14
Total current assets		418			278

Non-current assets
Property and equipment, net		2			3
Intangible assets, net		238			193
Total non-current asset		240			196

Total assets		658			474

LIABILITIES AND DEFICIENCY
Current liabilities
Trade payables		24			51
Other accounts payable		679			694
Short-term loans from related party		79			79
Convertible loans at amortized cost		811			796
Convertible loans – At fair value		2,160			1,203
Financial liability at fair value		72			204
Total current liabilities		3,825			3,027
Total liabilities		3,825			3,027

DEFICIENCY
AppYea Inc. Stockholders’ Deficiency:
Convertible preferred stock, $0.0001 par value		-			-
Common stock, $0.0001 par value		41			31
Stock payables		657			559
Additional Paid in Capital		3,719			3,197
Accumulated deficit		(7,570	)		(6,326	)
Total AppYea Inc. stockholders’ deficiency		(3,153	)		(2,539	)
Non-controlling interests		(14	)		(14	)

Total Deficiency		(3,167	)		(2,553	)

Total liabilities and deficiency		658			474

The accompanying notes are an integral part of the financial statements.

APPYEA INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(U.S. dollars in thousands)

	2024			2023
	For the three months ended March 31,
	2024			2023
	Unaudited			Unaudited

Sales		13			-
Cost of sales		(3	)		-
Gross profit		10			-

Research and development expenses		(60	)		(9	)
Sales and marketing		(54	)		-
General and administrative expenses		(294	)		(427	)

Operating loss		(398	)		(436	)

Change in fair value of convertible loans and warrant liability		(824	)		166

Financial income (expenses), net		(22	)		(19	)

Loss before income tax benefit		(1,244	)		(289	)

Income tax benefit		-

Net loss		(1,244	)		(289	)

Net loss attributable to AppYea Inc.		(1,244	)		(289	)

Net Loss per Common Share:

Basic and Diluted		(0.003	)		(0.001	)

Weighted Average number of Common Shares Outstanding basic and diluted		380,266,957			225,248,108

The accompanying notes are an integral part of the financial statements.

APPYEA INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN DEFICIENCY

(U.S. dollars in thousands except share data)

	Number			Amount		Number		Amount		Capital			Payables			Deficit			Total			interests			Equity
	Preferred Stock					Common Stock				Additional Paid in			Shares to be			Accumulated						Non-controlling			Total
	Number			Amount		Number		Amount		Capital			issued			Deficit			Total			interests			Equity
	Unaudited
Balance as of January 1, 2024		258,745			-		328,836,657		31		3,197			559			(6,326	)		(2,539	)		(14	)		(2,553	)

Share based Compensation		-			-		-		-		147			-			-			147			-			147
Net loss		-			-		-		-		-			-			(1,244	)		(1,244	)		-			(1,244	)
Shares to be issued
Shares to be issued to service providers		-					-		-		-			25			-			25			-			25
Issuance of Shares		-					60,143,100		6		379			(2	)		-			383			-			383
Shares to be issued to investors							-		-		-			75			-			75			-			75
Options exercise							500,000		-		-			-			-			-			-			-
Share issuance upon conversion of Preferred stock		(28,147	)		-		42,217,500		4		(4	)		-			-			-			-			-

Balance as of March 31, 2024		230,598			-		431,697,257		41		3,719			657			(7,570	)		(3,153	)		(14	)		(3,167	)

	Preferred Stock				Common Stock				Additional Paid in		Shares to be		Accumulated						Non-controlling			Total
	Number		Amount		Number		Amount		Capital		issued		Deficit			Total			interests			Equity
	Unaudited
Balance as of January 1, 2023		300,000				220,930,798		21		1,912		27		(4,509	)		(2,549	)		(14	)		(2,563	)
Balance		300,000				220,930,798		21		1,912		27		(4,509	)		(2,549	)		(14	)		(2,563	)

Share based Compensation		-		-		-		-		279		-		-			279			-			279
Net loss		-		-		-		-		-		-		(289	)		(289	)		-			(289	)
Shares to be issued		-		-		-		-		-		1		-			1			-			1
Share issuance upon conversion of Convertible notes.		-		-		8,634,616		1		160		-		-			161			-			161

Balance as of March 31, 2023		300,000		-		229,565,414		22		2,351		28		(4,798	)		(2,397	)		(14	)		(2,411	)
Balance		300,000		-		229,565,414		22		2,351		28		(4,798	)		(2,397	)		(14	)		(2,411	)

The accompanying notes are an integral part of the financial statements.

APPYEA INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(U.S. dollars in thousands)

	2024			2023
	For The Three Months Ended March 31,
	2024			2023
	Unaudited
Cash flows from operating activities:
Net loss		(1,244	)		(289	)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization		6			6
Share based compensation		172			279
Change in fair value of convertible loans and warrant liability		824			(147	)
Financial expenses, net		14			-

Changes in operating assets and liabilities:
Other current assets		11			1
Accounts payables		(24	)		74
Accounts payables – related party		(16	)		(21	)
Net cash used in operating activities		(257	)		(97	)

Cash flows from investing activities:
Research and development expenses capitalization		(50	)		-
Net cash used in investing activities		(50	)		-

Cash flows from financing activities:
Proceeds from issuance of Common Stock		381			-
Proceeds from convertible Note received, net of issuance expenses		-			141
Proceeds on account of Shares to be issued		75			-
Net cash provided by financing activities		456			141

Foreign exchange on Cash and cash equivalents		3			(4	)
Change in cash and cash equivalents		152			40
Cash and cash equivalents at beginning of period		222			60

Cash and cash equivalents at end of period		373			100

The accompanying notes are an integral part of the financial statements.

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 1 - GENERAL

AppYea, Inc. (“AppYea”, “the Company”, “we” or “us”) was incorporated in the State of South Dakota on November 26, 2012 to engage in the acquisition, purchase, maintenance and creation of mobile software applications. The Company is in the development stage with no significant revenues and no operating history. On November 1, 2021 the Company was redomiciled in the State of Nevada.

The Company’s common stock is traded on the OTC Markets, OTCQB tier, under the symbol “APYP”.

SleepX LTD is a company formed under the laws of the State of Israel and a wholly owned subsidiary of the Company (“SleepX”). SleepX is a research and development company that has developed a proprietary product for monitoring and treating sleep apnea and snoring. The technology is protected by several international patents and the Company started serial production in 2023. Subject to raising working capital, of which no assurance can be provided, the Company intends to focus on further development and commercialization of its products.

SleepX has incorporated, together with an unrelated third party, a privately held company under the laws of the State of Israel named Ta-nooma Ltd. (“Ta-nooma”). Ta-nooma has developed sleeping monitoring technology for which patent applications were filed and has no revenue from operations. Since its incorporation and as of the financial statements date, Sleepx holds 66.7% of the voting interest of Ta-nooma.

Strategic Development

The company flagship product is AppySleep – A Biofeedback snoring treatment wristband, combined with the AppySleep App (“AppySleep”).

The AppySleep product is currently in serial manufacturing and commercial stage.

Financial position

The financial statements are presented on a going-concern basis. To date, the Company has not generated any significant revenues, suffered recurring losses from operations, incurred negative cash flows from operating activities, and is dependent upon external sources for financing its operations. As of March 31, 2024, the Company had an accumulated deficit of $7,570,000 and a stockholders’ deficiency of $3,153,000. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The Company intends to continue to finance its operating activities by raising capital. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities on commercially reasonable terms or at all. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of its product candidates or may be required to implement cost reduction measures and may be required to delay part of its development programs.

The financial statements do not include any adjustments for the values of assets and liabilities and their classification that may be necessary in the event that the Company is no longer able to continue its operations as a “going concern”.

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

The interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The interim financial statements do not include a full disclosure as required in annual financial statements and should be read with the annual financial statements of the Company as of December 31, 2023 from which the accompanying condensed consolidated balance sheet dated December 31, 2023, was derived. The accounting policies implemented in the interim financial statements are consistent with the accounting policies implemented in the annual financial statements as of December 31, 2023, except of the following accounting pronouncement adopted by the Company.

Recently Issued Accounting Pronouncements

Effective January 1, 2024, the Company adopted ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”), which is intended to address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. For convertible instruments, ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stocks, and enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance on the basis of feedback from financial statement users. The adoption of this new accounting guidance did not have an effect on the consolidated financial statements.

Effective January 1, 2023, the Company adopted ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326),” referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaced the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under current generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. The Company determined the adoption of this new accounting guidance and the effect on its financial statements throughout the period until implementation, and have no impact on the financial statements.

In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” related to improvements to income tax disclosures. The amendments in this update require enhanced jurisdictional and other disaggregated disclosures for the effective tax rate reconciliation and income taxes paid. The amendments in this update are effective for fiscal years beginning after December 15, 2024. The adoption of this pronouncement is not expected to have a material impact on the Company’s financial statements.

Use of Estimates in Preparation of Financial Statements

The preparation of consolidated financial statements in conformity with U.S. GAAP accounting principles requires management to make estimates and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition

The Company recognizes revenue under ASC 606, Revenue Recognition at the amount to which it expects to be entitled when control of the products or services is transferred to its customers.

We determine revenue recognition through the following steps: (1) identification of the contract with a customer; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when, or as, a performance obligation is satisfied.

Our contracts are typically governed by a customer purchase order. The contract generally specifies the delivery of what constitutes a single performance obligation. If an arrangement involves multiple performance obligations, the items are analyzed to determine the separate units of accounting, whether the items have value on a standalone basis and whether there is objective and reliable evidence of their standalone selling price. The total contract transaction price is allocated to the identified performance obligations based upon the relative standalone selling prices of the performance obligations. The standalone selling price is based on an observable price for services sold to other comparable customers.

As discussed in more detail below, revenue is recognized when a customer obtains control of promised goods or services under the terms of a contract and is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. We do not have any material extended payment terms, as payment is due at or shortly after the time of the sale. Sales, value-added and other taxes collected concurrently with revenue producing activities are excluded from revenue.

A contract liability is recognized as deferred revenue when we invoice customers, or receive customer cash payments, in advance of satisfying the related performance obligation(s) under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation.

We have one main revenue stream: wristband sales, with the AppySleep App. For this revenue stream, our performance obligations are satisfied at a point in time, and therefore, revenue is recognized at point in time when a customer takes control of the good or asset created by the service. Factors that may indicate transfer of control are when we have the right to receive payment for the good or service, when the legal title of the asset has been transferred, physical possession of the asset has been transferred, the customer obtains the significant risks and rewards of ownership of the asset, and the customer accepts the asset. For customers, control is transferred upon delivery.

We leverage drop-ship shipments with our partners and suppliers to deliver wristbands to our customers without having to physically hold the inventory at our warehouses, thereby increasing efficiency and reducing costs. We recognize revenue for drop-ship arrangements on a gross basis as the principal in the transaction when the product is received by the customer because we control the product prior to transfer to the customer. We also assume primary responsibility for the fulfillment in the arrangement, we assume inventory risk if something were to happen to the hardware during shipping, we set the price of the product charged to the customer.

The Company intend to recognize records reductions to Products net sales related to future product returns, price protection and other customer incentive programs based on the Company’s expectations and historical experience.

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 3 - RELATED PARTY BALANCES AND TRANSACTIONS

Short-term loans from related parties

During 2021, SleepX borrowed from Nexense Technologies USA. Inc., a Delaware corporation which is majority owned by Boris Molchadsky, the Company’s Chairman. an aggregate amount of $47,623. According to the agreement, the loan shall be repaid in the event that the Company’s profits are sufficient to repay the aggregate loan amount and upon such terms and in such installments as shall be determined by the Board. The loan shall bear interest at an annual rate equal to the minimum rate approved by applicable law in Israel (5.18% in 2024).

During 2020, the minority shareholder of Ta-nooma advanced a loan to Ta-nooma in the amount of NIS 115,725. The loan does not carry any interest expense and the repayment terms have yet to be determined. As of March 31, 2024, the loan balance amounted to NIS 115,725 ($31,906).

Balances with related parties

	March 31, 2024		December 31, 2023
	In U.S. dollars in thousands

Liabilities:
Employees and payroll accruals		267		498
Related party payables		208		129
Short term loans		79		79

Transactions with related parties

	2024		2023
	For the three months ended March 31,
	2024		2023
	In U.S. dollars in thousands
Expenses:
Salaries and related cost (including stock-based compensation in the amount of $116,000 and $721,000, respectively)		190		1,067

Both the Chairman and the chief financial officer are directors in the Company and do not receive compensation for their directorship roles. Company’s Bylaws provide that a director or officer shall be indemnified and held harmless by the Corporation, to the fullest extent permitted by the laws of the State of Nevada.

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 4 - CONVERTIBLE LOANS AND WARRANTS

The following table summarizes fair value measurements by level as of March 31, 2024 and December 31, 2023 measured at fair value on a recurring basis:

SCHEDULE OF FAIR VALUE RECURRING BASIS

December 31, 2023	Level 1		Level 2		Level 3		Total
	In U.S. dollars
Assets
None		-		-		-		-

Liabilities
Convertible Loans At fair value		-		-		1,203		1,203
Financial liability				-		204		204

March 31, 2024	Level 1		Level 2		Level 3		Total
	In U.S. dollars
Assets
None		-		-		-		-

Liabilities
Convertible Loans At fair value		-		-		2,160		2,160
Financial liability				-		72		72

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 4

CONVERTIBLE LOANS AND WARRANTS (cont.)

The Convertible Loans changes consist of the following as of March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
	Convertible Loans at Fair Value
	March 31, 2024		December 31, 2023
	$000
Opening Balance, (including short term loans from related party which is also convertible)		1,203		2,257
Additional convertible loans (a)		-		153
Conversion of convertible loan (b)		-		(243	)
Decrease of notes purchased		-		(530	)
Change in fair value of convertible loans liability		957		(434	)
Closing balance		2,160		1,203

(a)

During the quarter ended March 31, 2024, and the year ended December 31, 2023, the Company raised a principal amount of nill and $152,750, respectively.

(b)

During the quarter ended March 31, 2024, and the year ended December 31, 2023 a total amount of nill and $242,538 (which were converted into 8,634,616 shares of common stock), respectively.

The estimated fair values of the Convertible loans were measured according to the Monte Carlo Model using the following assumptions:

	As of			As of
	March 31, 2024			December 31, 2023
Expected term (in years)		0.25			0.5
Expected average (Monte Carlo) volatility		83	%		213	%
Expected dividend yield		-			-
Risk-free interest rate		5.46	%		5.26	%
WACC		27	%		27	%

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 4

CONVERTIBLE LOANS AND WARRANTS (cont.)

The following table summarizes information relating to outstanding and exercisable warrants as of December 31, 2023:

Warrants Outstanding and Exercisable
Number of Warrants		Weighted Average Remaining Contractual life (in years)		Weighted Average Exercise Price		Valuation as of December 31, 2023
	8,334		2.16		0.6	$	23
	32,500		2.61		0.6	$	116
	7,000,000		0.46		0.015	$	203,718

The following table summarizes information relating to outstanding warrants as of March 31, 2024:

Warrants Outstanding
Number of Warrants		Weighted Average Remaining Contractual life (in years)		Weighted Average Exercise Price		Valuation as of March 31, 2024

	7,000,000		0.21		0.01024	$	71,702
	8,334		1.91		0.6	$	23
	32,500		2.36		0.6	$	116

The estimated fair values of the Warrants were measured according to the data as follows:

	As of			As of
	March 31, 2024			December 31, 2023
Expected term		0.21			0.46
Expected average volatility		87	%		224	%
Expected dividend yield		-			-
Risk-free interest rate		4.19	%		5.3	%
Common Stock Market Value	$	0.01024		$	0.015
Warrants rights outstanding measurement input	$	0.01024		$	0.015

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 4

CONVERTIBLE LOANS AND WARRANTS (cont.)

The Convertible Loans at amortized cost changes consist of the following as of March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
	$000
Opening balance		796		-
Transition from convertible loans measured at fair value to measurement at amortized cost		-		530
Beneficial conversion feature		-		(66	)
Financial expenses related to transition from fair value measurement to amortized cost		-		304
Accrued interest through profit or loss		15		28
Closing balance		811		796

NOTE 5 - STOCK BASED COMPENSATION

The table below depicts the number of options granted to employees and service providers:

SCHEDULE OF NUMBER OF OPTIONS

	Three months ended March 31, 2024
	Number of			Weighted average exercise price
	options			in USD

Options outstanding at January 1, 2024		62,349,647		$	0.0007
Options granted during the period		7,900,000		$	0.00373
Options exercised during the period*		(500,000	)	$	0.0001
Options outstanding at the end of period		69,749,647		$	0.00107
Options exercisable at the end of period		25,650,311		$	0.00136

*	A board member exercised his options into shares during the quarter

For the three months ended March 31, 2024 and 2023 the company recognized expenses, to such options, in the amount of $147,000 and $279,000, respectively. The expense is non-cash stock-based compensation expense resulting from options awards to the Chief Executive Officer, Chief Financial Officer and advisors The expense represents the aggregate grant date fair value for the option awards granted and vested during the fiscal years presented, determined in accordance with FASB ASC Topic 718.

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 6 - SIGNIFICANT EVENTS DURING THE PERIOD

On January 1, 2024, the Company engaged with a consultant. For his services he was granted stock option to purchase 2,300,000 of the Company’s Common Stock, valued at $34,350. The Options are vested on a monthly basis, over a period of 30 months as of the commencement date ending June 30, 2026. The options are exercisable at a per share exercise price of $0.01 and are otherwise subject to the other terms and conditions specified in an Option Grant Agreement to be entered into between optionee and the Company.

On January 1, 2024, the Company engaged with an additional consultant. For his services, he was granted a stock option to purchase 600,000 of the Company’s Common Stock, valued at $8,961. The Options are vested on a monthly basis, over a period of 30 months as of the Commencement Date ending June 30, 2026. The Option are exercisable at a per share exercise price of $0.01 and are otherwise subject to the other terms and conditions specified in an Option Grant Agreement to be entered into between optionee and the Company.

	C.	On January 1, 2024, the Company engaged with a note holder as a consultant. For his services, he was granted a stock option to purchase 5,000,000 of the Company’s Common Stock, valued at $74,675. Upon grant, the Options vest on a monthly basis, over a period of 12 months as of the Commencement Date ending December 31, 2024. The Option are exercisable at a per share exercise price of $0.0001.

	D.	During the first quarter of 2024, the company received an additional investment of $456,431 and registered shares to be issued from that investment in the amount of 7,500,000 common shares.

	E.	On August 11, 2022, a lawsuit was filed in the Tel Aviv Magistrate’s Court against our Chairman and majority shareholder, Boris Molchadsky, G.P.I.S Ltd., an entity controlled by Mr. Molchadsky, Nexsense, Inc. (the former shareholder of SleepX Ltd.) and SleepX, Ltd., our subsidiary (collectively, the “Defendants”) [Civil lawsuit number 25441-08-22]. The suit was filed by a fund operating out of Israel. A copy of the claim was served to the defendants only six months after it was submitted to court, on February 21, 2023. The lawsuit is based on the alleged breach of partnership and loan agreements as well as other related allegations, including violation of agreements reached in a mediation proceeding that took place in 2015. On July 24, 2023, the Defendants (except for Nexsense, Inc.) filed a statement of defense, denying the allegations and argued that the claim should be dismissed, due to the statute of limitations, lack of cause of action, lack of jurisdiction, delay in filing the claim, and respecting SleepX, also due to the lack of legal rivalry between SleepX and the plaintiff. Recently, the Magistrate’s Court in Tel Aviv accepted the request regarding lack of material jurisdiction, and the claim was then transferred to the economic department of the District Court in Tel Aviv. A preliminary hearing was held on February 14, 2024. The presiding judge did not rule on the preliminary pleadings and urged the parties to attempt mediation before the ruling. The parties are considering different mediators (which must be mutually agreed to) and following the selection of a mediator, the parties will schedule a date for the mediation. The Company cannot, at this stage, know the effects, if any, of these actions on its subsidiary SleepX and / or the Company, and accordingly, no provision was recorded.

NOTE 7 - SUBSEQUENT EVENTS

	A.	On May 13, 2024, Mr. Neil Kline announced the company on his resignation from the board of directors of the company. In Parallel, Mr. Kline signed an advisor agreement with the company to serve as an advisor of the Board, and provide services related to the development of company future products, creating marketing tools for company needs, and assist with filings and projects of the company.

	B.	On May 14, 2024, the Board of the Company (the “Boad”) approved the conversion of outstanding amounts owed to its officers and directors for unpaid compensation for options of the Company’s common stock, as follows: Boris Molchadsky, the Company chairman, and Asaf Porat, the Company CFO, agreed to convert a portion their unpaid compensation into options for shares of the Company’s common stock at a per share conversion rate of $0.07 and $0.04, respectively, and Adi Shemer, the Company CEO, has agreed to convert the entire unpaid compensation to him into options for shares of the Company’s common stock at per share conversation date of $0.04, in each case under a Company compensation Plan to be approved by the Company and its shareholders and qualified under Sections 102 and 103 of the Israeli tax authorities (such being the “Qualified Equity Interests”). There remains outstanding unpaid compensation to each of Mr. Molchadsky and Porat in the amount of $70,000 and $50,000, respectively. It was agreed that the unpaid compensation which was not converted would be paid in 20 equal monthly instalments, subject to payment of payroll, social security and other taxes, commencing on the 30^th day following the earlier to occur of (i) the closing of an equity raise by the Company with proceeds to the Company of at least $1.5 million, (ii) the completion of seven consecutive (7) months positive cash flow for the Company in such amount as will allow the Company to cover its operating expenses and (iii) termination of employment by the Company of for any reason other than cause. As of April 1, 2024 the Company converted the outstanding amounts related to its officers and directors and issued 6,959,692 options, which are exercisable with an exercise ratio of 1:1.

	C.	In addition, the Board approved the issuance of stock option to purchase 6,000,000 shares of the Company’s common stock, at a per share exercise price of $0.0001, to Adi Shemer, the Company CEO. Under his terms of his employment agreement, Mr. Shemer is entitled to these options following the issuance by the Company of at least 100 million shares of common stock in respect of third-party investments in the Company, which was satisfied in February 2024. The options will vest in full on July 1, 2024. For the three-month ended March 31, 2024 the Company recorded an expense related to the issuance of $49,492 out of a total expense of $197,966.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-looking Statements

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws, and is subject to the safe-harbor created by such Act and laws. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other variations thereon or comparable terminology. The statements herein and their implications are merely predictions and therefore inherently subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results, performance levels of activity, or our achievements, or industry results to be materially different from those contemplated by the forward-looking statements. Except as required by law, we undertake no obligation to release publicly the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Further information on potential factors that could affect our business is described under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission, or the SEC, on April 1, 2024 As used in this quarterly report, the terms “we”, “us”, “our”, the “Company” and “AppYea” mean AppYea, Inc. and our wholly-owned subsidiaries Sleepx LTD and Ta-Nooma LTD unless otherwise indicated or as otherwise required by the context.

Overview

AppYea, Inc. is a digital health company, focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring and fundamentally improve quality of life.

Our solutions are based on our proprietary intellectual property portfolio comprised of Artificial Intelligence (AI) and sensing technologies for the tracking, analysis, and diagnosis of vital signs and other physical parameters during sleep time, offering extreme accuracy at affordable cost.

AI is a broad term generally used to describe conditions where a machine mimics “cognitive” functions associated with human intelligence, such as “learning” and “problem solving. Basic AI includes machine learning, where a machine uses algorithms to parse data, learn from it, and then make a determination or prediction about a given phenomenon. The machine is “trained” using large amounts of data and algorithms that provide it with the ability to learn how to perform the task.

General Background

Snoring is a general disorder caused due to repetitive collapsing and narrowing of the upper airway. Individuals with snoring problems are at increased risk of accidental injury, depression and anxiety, heart disease and stroke. Currently available treatments include surgical and non-surgical devices.

According to Fior Markets, a market intelligence company, the Global Anti-Snoring Treatment Market is expected to grow from USD 4.3 billion in 2020 to USD 8.6 billion by 2028, with a 9.07% CAGR between 2021 and 2028. While North America had the largest market share of 28.12% in 2020, Asia-Pacific region is witnessing significant growth due to the increasing prevalence of obesity and sedentary lifestyles in emerging economies.

Currently available anti-snoring devices consist mainly of oral appliances that are recommended for use by patients suffering from snoring or obstructive sleep apnea. These appliances are put before sleep and have a simple function of pushing either the lower jaw or the tongue forward. This keeps the epiglottis parted from the uvula and prevents the snoring sound created by the vibration of soft tissues of palate.

Sleep apnea is a severe sleep condition in which individuals frequently stop breathing in their sleeping, this leads to insufficient oxygen supply to the brain and the rest of the body which, in turn may lead to critical problems. There are three main types of apneas: (i) Obstructive Sleep Apnea (“OSA”), the most common form caused by the throat muscles relaxing during sleep; (ii) Central sleep apnea, which occurs when the brain doesn’t send the proper signals to the muscles that control the breathing; and (iii) complex sleep apnea syndrome, which occurs when an individual suffers from both OSA and central sleep apnea. While OSA is a common disorder in the elderly population, affecting approximately 13 to 32% of people aged over 65, sleep apnea can occur at any age and affects approximately 25% of men and nearly 10% of women.

In 2020, North America dominated the sleep apnea device market, as it accounted for 49% of the revenue, the global market size was valued at USD 3.7 billion and is expected to expand by 6.2% CAGR, according to a report by Grand View Research Inc., reaching USD 6.1 billion by 2028.

The global sleep apnea and snoring market is driven in large part by solutions that can be applied in at home-settings or healthcare settings, as these tools will drive decisions regarding specific treatments and the associated outlays. However, despite advances in medical imaging and other diagnostic tools, misdiagnosis remains a common occurrence. We believe that improved diagnoses and outcomes are achievable through the adoption of AI-based decision support tools.

Our Products and Product Candidates

Our initial focus is on the development of supporting solutions utilizing our proprietary platform. Our current business plan focuses on two principal devices and an App currently in development:

AppySleep – Biofeedback snoring treatment wristband, combined with the AppySleep App.

The AppySleep app uses unique algorithms developed by SleepX combined with sensors to monitor physiological parameters during sleep. Based on real time reactions, the wristband will vibrate, when necessary, in order to decrease the snoring and regulate breathing by gently bringing the user to a lighter sleep or change his sleep position and thus ceasing the snoring event.

The AppySleep product is currently in serial manufacturing stage and sales.

AppySleep LAB – Is a medical application, intended for downloading on a smartphone, and used to monitor breathing patterns in the sleep and identify sleep apnea episodes without direct contact to the user.

The AppySleep LAB product is to begin final calibration, following which we will file for 510(k) FDA approval.

AppySleep PRO – is a wristband for the treatment of sleep apnea using biofeedback in combination with AppySleep LAB app. The unique algorithms of AppySleep LAB, combined with the wristband sensors, monitor sleep apnea events and additional physiological parameters during sleep, and when necessary, the wristband vibrates according to real time events, in order to decrease and cease sleep apnea events.

The AppySleep PRO and AppySleep LAB are currently in development stages, following which it would be ready to begin the testing stage in preparation for filing for FDA approval.

Our Strategy

We started marketing of the AppySleep app and wristband in the first quarter of 2024. Concurrently, we plan to file a 510(k) FDA submission for the AppySleep LAB app for the non-contact diagnosis of sleep apnea during 2024, and an FDA process for AppySleep PRO for the treatment of sleep apnea during 2026.

Our goal over the next five years is to establish our technology and related products as the gold standard for the targeted sectors. The key elements of our strategy are as follows:

Develop and expand a balanced and diverse pipeline of products and product candidates. Our core platform technologies will include innovative anti-snoring and sleep apnea related devices and product candidates in various development and clinical stages. We plan to add products and product candidates to our pipeline by expanding our technologies being developed to additional indications and through investing in new technologies, products and product candidates. By maintaining this multi-product approach, we aim to provide a broad and comprehensive product offering, which we believe will result in multiple value inflection events, reduced risks to our potentially business associated with a particular product or product candidate and increased return on investment. Furthermore, product candidates that we develop may create attractive collaboration opportunities with diagnostics, medical devices and medical supplies companies.

Maintain a global, diverse network of specialists to accelerate knowledge synergies and innovation. We will utilize a global network of specialists to identify large and growing patient populations with significant unmet needs, evaluate and prioritize potential technologies, assist in designing development plans and diagnostic protocols and determine potential indications of our platform technologies to our target patient populations in various territories. We believe that maintaining this diverse network of specialists and industry specialists will allow us to continue to maximize knowledge and cost synergies, utilize shared commercial infrastructure across products, reduce risks of development and commercialization delays to our overall business and leverage our current and future platform technologies and technologies for additional products and product candidates.

Establish distribution channels to maximize the commercial potential of our products. We plan to seek out collaborative arrangements with major healthcare providers and consumer specialists to facilitate market adoption of our product candidates. We believe that such institutions are well positioned to directly benefit from improvements in accurate diagnosis and reduction of cost of care associated with the use of our product candidates. We also believe that the marginal cost of our product candidates compared to potential savings will make it economical for healthcare institutions to adopt our products regardless of whether or not additional costs of purchase of these products will be covered by third-party payors, such as government health care programs and commercial insurance companies. Through cooperation with healthcare providers, we aim to develop and prove an economic model beneficial to them. In parallel, we intend selling directly, through our website and other online webstores worldwide. Thereafter, we plan to engage with private insurance plans to develop reimbursement programs encouraging the use of our product candidates. We expect that adoption rates of our product candidates will increase if hospitals and other medical institutions are compensated, in full or in part, for additional costs incurred when purchasing our products.

We established a logistical distribution facility in the US.

The License Agreement

Our business derives from a licensing agreement entered into as of March 15, 2020, as subsequently amended (the “License Agreement”), by SleepX Ltd., our Israeli subsidiary, B.G. Negev Technologies and Applications Ltd., a company formed under the laws of the State of Israel (“BGN”) and Mor Research Application Ltd. a company formed under the laws of Israel (“Mor”; together with BGN, the Licensors”). BGN is a company wholly owned by Ben Gurion University of the Negev in Israel and Mor, is the technology transfer arm of the Clalit Health Services, an Israeli non-profit healthcare insurance and service provider. Under the License Agreement, our Israeli subsidiary was granted a worldwide royalty bearing and exclusive license exclusive worldwide license with the right to grant sub-licenses and with a term of 15 years, to certain intellectual property to research, develop, manufacture use, market, distribute, offer for sale and sell sensor and software solutions for monitoring snoring and sleep apnea.

On May 1, 2022, our Israeli subsidiary and the Licensors entered into an amendment to the License Agreement (the “Amended License Agreement”) to include under the license certain sleep apnea treatment solutions that by combining speech descriptors from three separate and distinct speech signal domains, these speech descriptors may provide the ability to estimate the severity of sleep apnea using statistical learning and speech analysis approaches.

As consideration for the licenses above, our Israeli subsidiary has agreed to pay the following to the Licensors:

(i)

A royalty of 3.0% of net sales received from the licensed products for a period of up to 15 years from initiation of sales in each state using licensed intellectual property;

	(ii)	25% of sublicense fees received prior to attainment of all regulatory approval for marketing and sale of the licensed products in the first jurisdiction where the licensed products are intended to be sold; thereafter, 15% of sublicense fees received after the date regulatory approval, but prior to the first commercial sale of the licensed products; and 10% of sublicense fees received after the first commercial sale;

	(iii)	An annual license fee, commencing on fifth anniversary of the License Agreement (i.e., March 2025) of $20,000, and thereafter on each anniversary date as follows

Year	Amount ($)
6	$	40,000
7	$	60,000
8	$	80,000
9-15	$	100,000

The Annual Fee is non-refundable, but it shall be credited each year due, against the royalty noted above, to the extent that such are payable, during that year.

(iv)

Milestone payment of $60,000 upon the attainment of regulatory approval from applicable authority in USA or Europe to market and sell the licensed products

As of the date of these financials, we have not achieved any of these milestones.

Under the License Agreement, the Licensors are entitled to terminate the License Agreement under certain conditions relating to a material change in the business of our Israeli subsidiary or a breach of any material obligation thereunder or to a bankruptcy event of our Israeli subsidiary. Under certain conditions, our Israeli subsidiary may terminate the License Agreement and return the licensed information to the Licensors.

In the event of an acquisition of all of the issued and outstanding share capital of the Israeli Subsidiary or of the Company and/or consolidation of the Israeli Subsidiary or the Company into or with another corporation (“Non IPO Exit”) or a listing of our common stock on a national exchange such as Nasdaq (the IPO Exit”), then the Licensors shall be entitled to an exit fee equal to 5% of the valuation of our company at the time of such exit and with respect to an IPO Exit, shares of common stock which will reflect in the aggregate 5% of the then outstanding common stock of the Company.

Key Financial Terms and Metrics

The following discussion summarizes the key factors our management believes are necessary for an understanding of our consolidated financial statements.

Revenues

We have generated $13,000 in revenues from product sales as of 03.31.2024.

Research and Development Expenses

The process of researching and developing our product candidates is lengthy, unpredictable, and subject to many risks. We expect to continue incurring substantial expenses for the next several years as we continue to develop our product candidates. We are unable, with any certainty, to estimate either the costs or the timelines in which those expenses will be incurred. The design and development of our devices will consume a large proportion of our current, as well as projected, resources.

Our research and development costs include costs are comprised of:

● internal recurring costs, such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities and maintenance costs attributable to research and development functions; and

● fees paid to external parties who provide us with contract services, such as programing, preclinical testing, manufacturing and related testing and clinical trial activities.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, employee benefits, equity compensation, and other personnel-related costs associated with executive, administrative and other support staff. Other significant general and administrative expenses include the costs associated with professional fees for accounting, auditing, insurance costs, consulting and legal services, along with facility and maintenance costs attributable to general and administrative functions.

Financial Expenses

Financial expenses consist primarily impact of exchange rate derived from re-measurement of monetary balance sheet items denominated in non-dollar currencies. Other financial expenses include bank’s fees and interest on long term loans. Financial income derives mainly from change in derivative value of convertible loans.

Results of Operations

Comparison of the Three Months Ended March 31, 2024 to the Three Months Ended March 31, 2023

	For the three- months period ended March 31
	2024			2023

Research and development expenses		60,000			9,000
General and administrative expenses		294,000			427,000

Financial income (expenses), net		(22,000	)		(19,000	)

Loss for the period		(1,244,000	)		(289,000	)

Revenues. We recorded revenues of $13,000 for the quarter ended March 31, 2024 from sales of our AppySleep wristband.

No revenues were recorded during the quarter ended March 31, 2023.

Research and Development Expenses, Research and development expenses increased from $9,000 during the three months ended March 31, 2023 to $60,000 for the quarter ended March 31, 2024. The increase in research and development expenses is primarily attributable to increased investment in intellectual property and development of our products during the first quarter of 2024.

Sales and Marketing. We recorded sales and marketing expenses of $54,000 for the quarter ended March 31, 2024 for sales of our AppySleep wristband through Amazon and our website.

No sales and marketing expenses were recorded during the quarter ended March 31, 2023.

General and Administrative Expenses. General and administrative expenses decreased from $427,000 for the three months ended March 31, 2023 to $294,000 for the for the quarter ended March 31, 2024. The decrease is primarily due to salary and professional services expenses, of which $147,281 were non-cash stock based non-cash compensation expenses resulting from options awards to our management and advisors.

Loss. Loss for the three months ended March 31, 2024 was $1,244,000 and is primarily attributable to change in fair value of convertible loans caused mainly by the rise in the stock price.

Liquidity and Capital Resources

From inception, we have funded our operations from a combination of loans and sales of equity.

As of March 31, 2024, we had a total of $373,000 in cash resources and approximately $3,825,000 of liabilities, all of which are current liabilities.

AppYea has experienced operating losses since its inception and had a total accumulated deficit of $7,570,000 as of March 31, 2024. We expect to incur additional costs and require additional capital. We have incurred losses in nearly every year since inception. These losses have resulted in significant cash used in operations. During the fiscal quarters ended March 31, 2024 and 2023, our cash used in operations was approximately $257,000 and $97,000, respectively. We need to continue and amplify our research and development efforts for our product candidates (which are in various stages of development), strengthen our patent portfolio, establish operations processes and pursue FDA clearance and international regulatory approvals as we continue to conduct these activities, we expect the cash needed to fund operations to increase significantly over the next several years.

The following table provides a summary of operating, investing, and financing cash flows for the period ended March 31, 2024 and 2023 respectively:

	For the three months ended
	March 31, 2024		March 31, 2023
	US Dollars
Net cash used in operating activities	$	257,000		97,000
Net cash used in investment activities	$	50,000		0
Net cash provided by Financing Activities	$	456,000		141,000

Between June 2023 and March 2024, we raised an aggregate of $955,330 from private placement of shares of our common stock at a per share price of $0.01 and the issuance of warrants, exercisable for a two year period from the date of issuance for an identical number of shares at a per share exercise price of $0.04, and additional $225,000 from public capital raised through the company effective prospectus. In respect of the raise the investors are entitled to an aggregate 118,032,953 shares of our common stock and identical number of warrants, of which 86,776,100 have already been issued. The subscription proceeds are being used to complete the IOS design and development of our biofeedback snoring treatment wristband (AppySleep product) as well as general corporate matters.

Management believes that funds on hand, will enable us to fund our operations and capital expenditure requirements through the end of the third quarter of 2024. We need to raise additional operating capital in order to maintain operations as presently conducted and to realize our business plan.

Our accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of these consolidated financial statements. However, the Company has incurred substantial losses. Our current liabilities exceed our current assets and available cash is not sufficient to fund the expected future operations. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.

We cannot be sure that future funding will be available to us on acceptable terms, or at all. Due to often volatile nature of the financial markets, equity and debt financing may be difficult to obtain.

We may seek to raise any necessary additional capital through a combination of private or public equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights, future revenue streams, or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through private or public equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

Going Concern

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. We have a stockholders’ deficit of $3,153,000 and a working capital deficit of $3,407,000 on March 31 2024, as well as negative operating cash flows. Our report from our independent registered public accounting firm for the Quarter ended March 31, 2024, includes an explanatory paragraph stating the Company has recurring losses and limited operations which raise substantial doubt about its ability to continue as a going concern. If the Company is unable to obtain adequate capital, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC’s rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Interim Chief Executive Officer, to allow timely decisions regarding required disclosure. Management, with the participation of our Interim Chief Executive Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as of March 31, 2024. Based on that evaluation, our management, including our Chief Executive Officer, concluded that our disclosure controls and procedures were not effective as of March 31, 2024.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As disclosed in Item 9A of our Annual Report on Form 10-K/A for the year ended December 31, 2023 filed with the Securities and Exchange Commission on May 17, 2024, our management concluded that our internal control over financial reporting was not effective at December 31, 2023. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

As a result of our evaluation, we identified a material weakness in our controls related to segregation of duties and other immaterial weaknesses in several areas of data management and documentation. Our management is composed of a small number of professionals resulting in a situation where limitations on segregation of duties exist. Accordingly, and as a result of the material weakness identified above, we have concluded that the control deficiencies result in a reasonable possibility that a material misstatement of the annual or interim financial statements may not be prevented on a timely basis by the Company’s internal controls. We continue to employ and refine a structure in which critical accounting policies, issues and estimates are identified, and together with other complex areas, are subject to multiple reviews by executives. We expect to be materially dependent upon third parties to provide us with accounting consulting services for the foreseeable future which we believe will mitigate the impact of the material weaknesses discussed above.

Changes in Internal Control Over Financial Reporting

Except for the material weakness noted above, during the quarter ended March 31, 2024, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In August 11, 2022, a lawsuit was filed in the Tel Aviv Magistrate’s Court against our Chairman and majority shareholder, Boris Molchadsky, G.P.I.S Ltd., an entity controlled by Mr. Molchadsky, Nexsense, Inc. (the former shareholder of SleepX Ltd.) and SleepX, Ltd., our subsidiary (collectively, the “Defendants”) [Civil lawsuit number 25441-08-22]. The suit was filed by a fund operating out of Israel. A copy of the claim was served to the defendants only six months after it was submitted to court, on February 21, 2023.

The lawsuit is based on the alleged breach of partnership and loan agreements as well as other related allegations, including violation of agreements reached in a mediation proceeding that took place in 2015.

The suit alleges that the Defendants, amongst other things, did not disclose to the plaintiff certain transactions to which the Plaintiff was presumably entitled to compensation and hence the plaintiff demanded an accounting of the transactions and refund of amounts invested. With respect to SleepX. the plaintiff alleged that it made a deal with Nexsense, Inc. which wasn’t disclosed to the plaintiff, while allegedly the technology and patents of Nexsense, Inc. were transferred to SleepX (which was established shortly before the reverse merger between AppYea and SleepX), thus allegedly aimed to the concealment of assets from the plaintiff.

On July 24, 2023, the Defendants (except for Nexsense, Inc.) filed a statement of defense, denying the allegations and argued that the claim should be dismissed, due to the statute of limitations, lack of cause of action, lack of jurisdiction, delay in filing the claim, and respecting SleepX, also due to the lack of legal rivalry between SleepX and the plaintiff.

In addition, the Defendants submitted several preliminary requests to dismiss the claim outright, including a plea to dismiss the claim on the grounds it was submitted to the magistrate court, which is not the competent court according to law, due to the economic nature of the claim. Nexsense, Inc. submitted a request to dismiss the claim against it because it was not properly served under the law (given the different service rules for defendants whose domicile is outside of Israel).

Recently, the Magistrate’s Court in Tel Aviv accepted the request regarding lack of material jurisdiction, and the claim was then transferred to the economic department of the District Court in Tel Aviv.

A preliminary hearing was held on February 14, 2024. The presiding judge did not rule on the preliminary pleadings and urged the parties to attempt mediation before the ruling. The parties are considering different mediators (which must be mutually agreed to) and following the selection of a mediator, the parties will schedule a date for the mediation.

We cannot, at this stage, know the effects, if any, of these actions on our subsidiary SleepX and / or the Company. However, SleepX together with the other Defendants, intend to vigorously defend against the lawsuit.

Aside from the disclosure above, from time to time we may become involved in various legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings or claims that we believe, either individually or in the aggregate, will have a material adverse effect on our business, financial condition, or results of operations.

From time to time we may become involved in various legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings or claims that we believe, either individually or in the aggregate, will have a material adverse effect on our business, financial condition, or results of operations.

ITEM 1A. RISK FACTORS

An investment in the Company’s Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our annual report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on April 1, 2024, as amended on May 17, 2024 in addition to other information contained in our reports and in this quarterly report in evaluating the Company and its business before purchasing shares of our Common Stock. There have been no material changes to our risk factors contained in such registration statement.

ITEM 2. UNREGISTERED SALES OF SECURITIES AND USE OF PROCEEDS

During the covered by this report period, we committed to issue to four investors an aggregate of 45,643,100 shares of our common stock upon investment of $456,431. As of the date of this report, 30,643,100 shares of common stocks have been issued with respect to this investment.

We relied upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”) by virtue of Section 4(a)(2) thereof and/or Regulation S promulgated by the SEC under the Act with respect to the issuance of such securities.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION:

During the fiscal quarter ended March 31, 2024, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

ITEM 6. EXHIBITS

Exhibit Index:

10.1*		Debt Conversion and Settlement Agreement between Bary Molchadsky and Appyea Inc.

10.2*		Debt Conversion a Agreement between Adi Shemer and Appyea Inc.

10.3*		Debt Conversion and Settlement Agreement between Asaf and Appyea Inc.

31.1		Certification of Chief Executive Officer (Principal Executive Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

31.2		Certification of Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

32.1		Certification of Chief Executive Officer (Principal Executive Officer), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Incorporated by reference from the Current Report on Form 8-K filed on May 17, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AppYea, Inc.

(Registrant)

By:	/s/ Adi Shemer	By:	/s/ Asaf Porat
	Adi Shemer		Asaf Porat
	Chief Executive Officer		Chief Financial Officer
	(Principal Executive Officer)		(Principal Financial and Accounting Officer)

Date: May 20, 2024		Date: May 20, 2024

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

OF REGISTRANT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(RULE 13a-14(a) or 15d-14(a) OF THE EXCHANGE ACT)

I, Adi Shemer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AppYea, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Adi Shemer
	Adi Shemer, Chief Executive Officer
	(Principal Executive Officer)

Date: May 20, 2024

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

OF REGISTRANT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(RULE 13a-14(a) or 15d-14(a) OF THE EXCHANGE ACT)

I, Asaf Porat, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AppYea, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

By:	/s/ Asaf Porat
	Asaf Porat, Chief Financial Officer
	(Principal Financial and Accounting Officer)

Date: May 20, 2024

EXHIBIT 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned Principal Executive Officer of AppYea, Inc. (the “Company”) hereby certifies to such officer’s knowledge that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Adi Shemer
Adi Shemer, Chief Executive Officer
(Principal Executive Officer)

Dated: May 20, 2024

EXHIBIT 32.2

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Asaf Porat
Asaf Porat, Chief Financial Officer
(Principal Financial and Accounting Officer)

Dated: May 20, 2024

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2024	May 20, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	000-55403
Entity Registrant Name	APPYEA, Inc.
Entity Central Index Key	0001568969
Entity Tax Identification Number	46-1496846
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	16 Natan Alterman St
Entity Address, City or Town	Gan Yavne
Entity Address, Country	IL
City Area Code	(800)
Local Phone Number	674-3561
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		451,113,064

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 373	$ 222
Accounts receivables	1
Other accounts receivables	30	42
Inventory	14	14
Total current assets	418	278
Non-current assets
Property and equipment, net	2	3
Intangible assets, net	238	193
Total non-current asset	240	196
Total assets	658	474
Current liabilities
Trade payables	24	51
Other accounts payable	679	694
Convertible loans at amortized cost	811	796
Convertible loans – At fair value	2,160	1,203
Financial liability at fair value	72	204
Total current liabilities	3,825	3,027
Total liabilities	3,825	3,027
AppYea Inc. Stockholders’ Deficiency:
Convertible preferred stock, $0.0001 par value
Common stock, $0.0001 par value	41	31
Stock payables	657	559
Additional Paid in Capital	3,719	3,197
Accumulated deficit	(7,570)	(6,326)
Total AppYea Inc. stockholders’ deficiency	(3,153)	(2,539)
Non-controlling interests	(14)	(14)
Total Deficiency	(3,167)	(2,553)
Total liabilities and deficiency	658	474
Related Party [Member]
Current liabilities
Short-term loans from related party	$ 79	$ 79

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Common stock, par value	$ 0.0001	$ 0.0001

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Sales	$ 13
Cost of sales	(3)
Gross profit	10
Research and development expenses	(60)	(9)
Sales and marketing	(54)
General and administrative expenses	(294)	(427)
Operating loss	(398)	(436)
Change in fair value of convertible loans and warrant liability	(824)	166
Financial income (expenses), net	(22)	(19)
Loss before income tax benefit	(1,244)	(289)
Income tax benefit
Net loss	(1,244)	(289)
Net loss attributable to AppYea Inc.	$ (1,244)	$ (289)
Net Loss per Common Share:
Net Loss Per Common Share: Basic	$ (0.003)	$ (0.001)
Net Loss Per Common Share: Diluted	$ (0.003)	$ (0.001)
Weighted Average number of Common Shares Outstanding basic	380,266,957	225,248,108
Weighted Average number of Common Shares Outstanding diluted	380,266,957	225,248,108

Condensed Consolidated Statements of Changes in Deficiency (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Balance	$ (2,553)	$ (2,563)
Share based Compensation	147	279
Net loss	(1,244)	(289)
Shares to be issued		1
Shares to be issued to service providers	25
Issuance of Shares	383
Shares to be issued to investors	75
Options exercise
Share issuance upon conversion of Convertible notes.		161
Balance	(3,167)	$ (2,411)
Preferred Stock [Member]
Balance
Balance, shares	258,745	300,000
Share based Compensation
Net loss
Shares to be issued
Share issuance upon conversion of Convertible notes.
Share issuance upon conversion of Convertible notes, shares	(28,147)
Balance
Balance, shares	230,598	300,000
Common Stock [Member]
Balance	$ 31	$ 21
Balance, shares	328,836,657	220,930,798
Share based Compensation
Net loss
Shares to be issued
Shares to be issued to service providers
Issuance of Shares	$ 6
Issuance of Shares, shares	60,143,100
Shares to be issued to investors
Options exercise
Options exercise, shares	500,000
Share issuance upon conversion of Convertible notes.	$ 4	$ 1
Share issuance upon conversion of Convertible notes, shares	42,217,500	8,634,616
Balance	$ 41	$ 22
Balance, shares	431,697,257	229,565,414
Additional Paid-in Capital [Member]
Balance	$ 3,197	$ 1,912
Share based Compensation	147	279
Net loss
Shares to be issued
Shares to be issued to service providers
Issuance of Shares	379
Shares to be issued to investors
Options exercise
Share issuance upon conversion of Convertible notes.	(4)	160
Balance	3,719	2,351
Stock Payables [Member]
Balance	559	27
Share based Compensation
Net loss
Shares to be issued		1
Shares to be issued to service providers	25
Issuance of Shares	(2)
Shares to be issued to investors	75
Options exercise
Share issuance upon conversion of Convertible notes.
Balance	657	28
Retained Earnings [Member]
Balance	(6,326)	(4,509)
Share based Compensation
Net loss	(1,244)	(289)
Shares to be issued
Shares to be issued to service providers
Issuance of Shares
Shares to be issued to investors
Options exercise
Share issuance upon conversion of Convertible notes.
Balance	(7,570)	(4,798)
Parent [Member]
Balance	(2,539)	(2,549)
Share based Compensation	147	279
Net loss	(1,244)	(289)
Shares to be issued		1
Shares to be issued to service providers	25
Issuance of Shares	383
Shares to be issued to investors	75
Options exercise
Share issuance upon conversion of Convertible notes.		161
Balance	(3,153)	(2,397)
Noncontrolling Interest [Member]
Balance	(14)	(14)
Share based Compensation
Net loss
Shares to be issued
Shares to be issued to service providers
Issuance of Shares
Shares to be issued to investors
Options exercise
Share issuance upon conversion of Convertible notes.
Balance	$ (14)	$ (14)

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (1,244)	$ (289)
Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization	6	6
Share based compensation	172	279
Change in fair value of convertible loans and warrant liability	824	(147)
Financial expenses, net	14
Changes in operating assets and liabilities:
Other current assets	11	1
Accounts payables	(24)	74
Accounts payables – related party	(16)	(21)
Net cash used in operating activities	(257)	(97)
Cash flows from investing activities:
Research and development expenses capitalization	(50)
Net cash used in investing activities	(50)
Cash flows from financing activities:
Proceeds from issuance of Common Stock	381
Proceeds from convertible Note received, net of issuance expenses		141
Proceeds on account of Shares to be issued	75
Net cash provided by financing activities	456	141
Foreign exchange on Cash and cash equivalents	3	(4)
Change in cash and cash equivalents	152	40
Cash and cash equivalents at beginning of period	222	60
Cash and cash equivalents at end of period	$ 373	$ 100

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (1,244)	$ (289)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

GENERAL

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL

NOTE 1 - GENERAL

The Company’s common stock is traded on the OTC Markets, OTCQB tier, under the symbol “APYP”.

Strategic Development

The company flagship product is AppySleep – A Biofeedback snoring treatment wristband, combined with the AppySleep App (“AppySleep”).

The AppySleep product is currently in serial manufacturing and commercial stage.

Financial position

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

Recently Issued Accounting Pronouncements

Use of Estimates in Preparation of Financial Statements

Revenue Recognition

The Company recognizes revenue under ASC 606, Revenue Recognition at the amount to which it expects to be entitled when control of the products or services is transferred to its customers.

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

RELATED PARTY BALANCES AND TRANSACTIONS

3 Months Ended

Mar. 31, 2024

RELATED PARTY BALANCES AND TRANSACTIONS

NOTE 3 - RELATED PARTY BALANCES AND TRANSACTIONS

Short-term loans from related parties

Balances with related parties

	March 31, 2024		December 31, 2023
	In U.S. dollars in thousands

Liabilities:
Employees and payroll accruals		267		498
Related party payables		208		129
Short term loans		79		79

Transactions with related parties

	2024		2023
	For the three months ended March 31,
	2024		2023
	In U.S. dollars in thousands
Expenses:
Salaries and related cost (including stock-based compensation in the amount of $116,000 and $721,000, respectively)		190		1,067

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

CONVERTIBLE LOANS AND WARRANTS

3 Months Ended

Mar. 31, 2024

Convertible Loans And Warrants

CONVERTIBLE LOANS AND WARRANTS

NOTE 4 - CONVERTIBLE LOANS AND WARRANTS

The following table summarizes fair value measurements by level as of March 31, 2024 and December 31, 2023 measured at fair value on a recurring basis:

SCHEDULE OF FAIR VALUE RECURRING BASIS

December 31, 2023	Level 1		Level 2		Level 3		Total
	In U.S. dollars
Assets
None		-		-		-		-

Liabilities
Convertible Loans At fair value		-		-		1,203		1,203
Financial liability				-		204		204

March 31, 2024	Level 1		Level 2		Level 3		Total
	In U.S. dollars
Assets
None		-		-		-		-

Liabilities
Convertible Loans At fair value		-		-		2,160		2,160
Financial liability				-		72		72

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 4

CONVERTIBLE LOANS AND WARRANTS (cont.)

The Convertible Loans changes consist of the following as of March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
	Convertible Loans at Fair Value
	March 31, 2024		December 31, 2023
	$000
Opening Balance, (including short term loans from related party which is also convertible)		1,203		2,257
Additional convertible loans (a)		-		153
Conversion of convertible loan (b)		-		(243	)
Decrease of notes purchased		-		(530	)
Change in fair value of convertible loans liability		957		(434	)
Closing balance		2,160		1,203

(a)

During the quarter ended March 31, 2024, and the year ended December 31, 2023, the Company raised a principal amount of nill and $152,750, respectively.

(b)

During the quarter ended March 31, 2024, and the year ended December 31, 2023 a total amount of nill and $242,538 (which were converted into 8,634,616 shares of common stock), respectively.

The estimated fair values of the Convertible loans were measured according to the Monte Carlo Model using the following assumptions:

	As of			As of
	March 31, 2024			December 31, 2023
Expected term (in years)		0.25			0.5
Expected average (Monte Carlo) volatility		83	%		213	%
Expected dividend yield		-			-
Risk-free interest rate		5.46	%		5.26	%
WACC		27	%		27	%

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 4

CONVERTIBLE LOANS AND WARRANTS (cont.)

The following table summarizes information relating to outstanding and exercisable warrants as of December 31, 2023:

Warrants Outstanding and Exercisable
Number of Warrants		Weighted Average Remaining Contractual life (in years)		Weighted Average Exercise Price		Valuation as of December 31, 2023
	8,334		2.16		0.6	$	23
	32,500		2.61		0.6	$	116
	7,000,000		0.46		0.015	$	203,718

The following table summarizes information relating to outstanding warrants as of March 31, 2024:

Warrants Outstanding
Number of Warrants		Weighted Average Remaining Contractual life (in years)		Weighted Average Exercise Price		Valuation as of March 31, 2024

	7,000,000		0.21		0.01024	$	71,702
	8,334		1.91		0.6	$	23
	32,500		2.36		0.6	$	116

The estimated fair values of the Warrants were measured according to the data as follows:

	As of			As of
	March 31, 2024			December 31, 2023
Expected term		0.21			0.46
Expected average volatility		87	%		224	%
Expected dividend yield		-			-
Risk-free interest rate		4.19	%		5.3	%
Common Stock Market Value	$	0.01024		$	0.015
Warrants rights outstanding measurement input	$	0.01024		$	0.015

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

NOTE 4

CONVERTIBLE LOANS AND WARRANTS (cont.)

The Convertible Loans at amortized cost changes consist of the following as of March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
	$000
Opening balance		796		-
Transition from convertible loans measured at fair value to measurement at amortized cost		-		530
Beneficial conversion feature		-		(66	)
Financial expenses related to transition from fair value measurement to amortized cost		-		304
Accrued interest through profit or loss		15		28
Closing balance		811		796

STOCK BASED COMPENSATION

3 Months Ended

Mar. 31, 2024

Retirement Benefits [Abstract]

STOCK BASED COMPENSATION

NOTE 5 - STOCK BASED COMPENSATION

The table below depicts the number of options granted to employees and service providers:

SCHEDULE OF NUMBER OF OPTIONS

	Three months ended March 31, 2024
	Number of			Weighted average exercise price
	options			in USD

Options outstanding at January 1, 2024		62,349,647		$	0.0007
Options granted during the period		7,900,000		$	0.00373
Options exercised during the period*		(500,000	)	$	0.0001
Options outstanding at the end of period		69,749,647		$	0.00107
Options exercisable at the end of period		25,650,311		$	0.00136

*	A board member exercised his options into shares during the quarter

APPYEA INC.

NOTES TO THE FINANCIAL STATEMENTS

SIGNIFICANT EVENTS DURING THE PERIOD

3 Months Ended

Mar. 31, 2024

Significant Events During Period

SIGNIFICANT EVENTS DURING THE PERIOD

NOTE 6 - SIGNIFICANT EVENTS DURING THE PERIOD

	C.	On January 1, 2024, the Company engaged with a note holder as a consultant. For his services, he was granted a stock option to purchase 5,000,000 of the Company’s Common Stock, valued at $74,675. Upon grant, the Options vest on a monthly basis, over a period of 12 months as of the Commencement Date ending December 31, 2024. The Option are exercisable at a per share exercise price of $0.0001.

	D.	During the first quarter of 2024, the company received an additional investment of $456,431 and registered shares to be issued from that investment in the amount of 7,500,000 common shares.

	E.	On August 11, 2022, a lawsuit was filed in the Tel Aviv Magistrate’s Court against our Chairman and majority shareholder, Boris Molchadsky, G.P.I.S Ltd., an entity controlled by Mr. Molchadsky, Nexsense, Inc. (the former shareholder of SleepX Ltd.) and SleepX, Ltd., our subsidiary (collectively, the “Defendants”) [Civil lawsuit number 25441-08-22]. The suit was filed by a fund operating out of Israel. A copy of the claim was served to the defendants only six months after it was submitted to court, on February 21, 2023. The lawsuit is based on the alleged breach of partnership and loan agreements as well as other related allegations, including violation of agreements reached in a mediation proceeding that took place in 2015. On July 24, 2023, the Defendants (except for Nexsense, Inc.) filed a statement of defense, denying the allegations and argued that the claim should be dismissed, due to the statute of limitations, lack of cause of action, lack of jurisdiction, delay in filing the claim, and respecting SleepX, also due to the lack of legal rivalry between SleepX and the plaintiff. Recently, the Magistrate’s Court in Tel Aviv accepted the request regarding lack of material jurisdiction, and the claim was then transferred to the economic department of the District Court in Tel Aviv. A preliminary hearing was held on February 14, 2024. The presiding judge did not rule on the preliminary pleadings and urged the parties to attempt mediation before the ruling. The parties are considering different mediators (which must be mutually agreed to) and following the selection of a mediator, the parties will schedule a date for the mediation. The Company cannot, at this stage, know the effects, if any, of these actions on its subsidiary SleepX and / or the Company, and accordingly, no provision was recorded.

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2024

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 7 - SUBSEQUENT EVENTS

	A.	On May 13, 2024, Mr. Neil Kline announced the company on his resignation from the board of directors of the company. In Parallel, Mr. Kline signed an advisor agreement with the company to serve as an advisor of the Board, and provide services related to the development of company future products, creating marketing tools for company needs, and assist with filings and projects of the company.

	B.	On May 14, 2024, the Board of the Company (the “Boad”) approved the conversion of outstanding amounts owed to its officers and directors for unpaid compensation for options of the Company’s common stock, as follows: Boris Molchadsky, the Company chairman, and Asaf Porat, the Company CFO, agreed to convert a portion their unpaid compensation into options for shares of the Company’s common stock at a per share conversion rate of $0.07 and $0.04, respectively, and Adi Shemer, the Company CEO, has agreed to convert the entire unpaid compensation to him into options for shares of the Company’s common stock at per share conversation date of $0.04, in each case under a Company compensation Plan to be approved by the Company and its shareholders and qualified under Sections 102 and 103 of the Israeli tax authorities (such being the “Qualified Equity Interests”). There remains outstanding unpaid compensation to each of Mr. Molchadsky and Porat in the amount of $70,000 and $50,000, respectively. It was agreed that the unpaid compensation which was not converted would be paid in 20 equal monthly instalments, subject to payment of payroll, social security and other taxes, commencing on the 30^th day following the earlier to occur of (i) the closing of an equity raise by the Company with proceeds to the Company of at least $1.5 million, (ii) the completion of seven consecutive (7) months positive cash flow for the Company in such amount as will allow the Company to cover its operating expenses and (iii) termination of employment by the Company of for any reason other than cause. As of April 1, 2024 the Company converted the outstanding amounts related to its officers and directors and issued 6,959,692 options, which are exercisable with an exercise ratio of 1:1.

	C.	In addition, the Board approved the issuance of stock option to purchase 6,000,000 shares of the Company’s common stock, at a per share exercise price of $0.0001, to Adi Shemer, the Company CEO. Under his terms of his employment agreement, Mr. Shemer is entitled to these options following the issuance by the Company of at least 100 million shares of common stock in respect of third-party investments in the Company, which was satisfied in February 2024. The options will vest in full on July 1, 2024. For the three-month ended March 31, 2024 the Company recorded an expense related to the issuance of $49,492 out of a total expense of $197,966.

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Mar. 31, 2024
Accounting Policies [Abstract]
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Effective January 1, 2024, the Company adopted ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)” (“ASU 2020-06”), which is intended to address issues identified as a result of the complexity associated with applying GAAP for certain financial instruments with characteristics of liabilities and equity. For convertible instruments, ASU 2020-06 reduces the number of accounting models for convertible debt instruments and convertible preferred stocks, and enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance on the basis of feedback from financial statement users. The adoption of this new accounting guidance did not have an effect on the consolidated financial statements. Effective January 1, 2023, the Company adopted ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326),” referred to herein as ASU 2016-13, which significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaced the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments. Under ASU 2016-13 credit impairment is recognized as an allowance for credit losses, rather than as a direct write-down of the amortized cost basis of a financial asset. The impairment allowance is a valuation account deducted from the amortized cost basis of financial assets to present the net amount expected to be collected on the financial asset. Once the new pronouncement is adopted by the Company, the allowance for credit losses must be adjusted for management’s current estimate at each reporting date. The new guidance provides no threshold for recognition of impairment allowance. Therefore, entities must also measure expected credit losses on assets that have a low risk of loss. For instance, trade receivables that are either current or not yet due may not require an allowance reserve under current generally accepted accounting principles, but under the new standard, the Company will have to estimate an allowance for expected credit losses on trade receivables under ASU 2016-13. The Company determined the adoption of this new accounting guidance and the effect on its financial statements throughout the period until implementation, and have no impact on the financial statements. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” related to improvements to income tax disclosures. The amendments in this update require enhanced jurisdictional and other disaggregated disclosures for the effective tax rate reconciliation and income taxes paid. The amendments in this update are effective for fiscal years beginning after December 15, 2024. The adoption of this pronouncement is not expected to have a material impact on the Company’s financial statements.
Use of Estimates in Preparation of Financial Statements	Use of Estimates in Preparation of Financial Statements The preparation of consolidated financial statements in conformity with U.S. GAAP accounting principles requires management to make estimates and assumptions. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company recognizes revenue under ASC 606, Revenue Recognition at the amount to which it expects to be entitled when control of the products or services is transferred to its customers. We determine revenue recognition through the following steps: (1) identification of the contract with a customer; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when, or as, a performance obligation is satisfied. Our contracts are typically governed by a customer purchase order. The contract generally specifies the delivery of what constitutes a single performance obligation. If an arrangement involves multiple performance obligations, the items are analyzed to determine the separate units of accounting, whether the items have value on a standalone basis and whether there is objective and reliable evidence of their standalone selling price. The total contract transaction price is allocated to the identified performance obligations based upon the relative standalone selling prices of the performance obligations. The standalone selling price is based on an observable price for services sold to other comparable customers. As discussed in more detail below, revenue is recognized when a customer obtains control of promised goods or services under the terms of a contract and is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. We do not have any material extended payment terms, as payment is due at or shortly after the time of the sale. Sales, value-added and other taxes collected concurrently with revenue producing activities are excluded from revenue. A contract liability is recognized as deferred revenue when we invoice customers, or receive customer cash payments, in advance of satisfying the related performance obligation(s) under the terms of a contract. Deferred revenue is recognized as revenue when we have satisfied the related performance obligation. We have one main revenue stream: wristband sales, with the AppySleep App. For this revenue stream, our performance obligations are satisfied at a point in time, and therefore, revenue is recognized at point in time when a customer takes control of the good or asset created by the service. Factors that may indicate transfer of control are when we have the right to receive payment for the good or service, when the legal title of the asset has been transferred, physical possession of the asset has been transferred, the customer obtains the significant risks and rewards of ownership of the asset, and the customer accepts the asset. For customers, control is transferred upon delivery. We leverage drop-ship shipments with our partners and suppliers to deliver wristbands to our customers without having to physically hold the inventory at our warehouses, thereby increasing efficiency and reducing costs. We recognize revenue for drop-ship arrangements on a gross basis as the principal in the transaction when the product is received by the customer because we control the product prior to transfer to the customer. We also assume primary responsibility for the fulfillment in the arrangement, we assume inventory risk if something were to happen to the hardware during shipping, we set the price of the product charged to the customer. The Company intend to recognize records reductions to Products net sales related to future product returns, price protection and other customer incentive programs based on the Company’s expectations and historical experience.

RELATED PARTY BALANCES AND TRANSACTIONS (Tables)

3 Months Ended

Mar. 31, 2024

SCHEDULE OF BALANCE WITH RELATED PARTIES

	March 31, 2024		December 31, 2023
	In U.S. dollars in thousands

Liabilities:
Employees and payroll accruals		267		498
Related party payables		208		129
Short term loans		79		79

SCHEDULE OF TRANSACTION WITH RELATED PARTIES

	2024		2023
	For the three months ended March 31,
	2024		2023
	In U.S. dollars in thousands
Expenses:
Salaries and related cost (including stock-based compensation in the amount of $116,000 and $721,000, respectively)		190		1,067

CONVERTIBLE LOANS AND WARRANTS (Tables)

3 Months Ended

Mar. 31, 2024

Class of Warrant or Right [Line Items]

SCHEDULE OF FAIR VALUE RECURRING BASIS

December 31, 2023	Level 1		Level 2		Level 3		Total
	In U.S. dollars
Assets
None		-		-		-		-

Liabilities
Convertible Loans At fair value		-		-		1,203		1,203
Financial liability				-		204		204

March 31, 2024	Level 1		Level 2		Level 3		Total
	In U.S. dollars
Assets
None		-		-		-		-

Liabilities
Convertible Loans At fair value		-		-		2,160		2,160
Financial liability				-		72		72

SCHEDULE OF CONVERTIBLE LOANS AT FAIR VALUE

	March 31, 2024		December 31, 2023
	Convertible Loans at Fair Value
	March 31, 2024		December 31, 2023
	$000
Opening Balance, (including short term loans from related party which is also convertible)		1,203		2,257
Additional convertible loans (a)		-		153
Conversion of convertible loan (b)		-		(243	)
Decrease of notes purchased		-		(530	)
Change in fair value of convertible loans liability		957		(434	)
Closing balance		2,160		1,203

(a)

During the quarter ended March 31, 2024, and the year ended December 31, 2023, the Company raised a principal amount of nill and $152,750, respectively.

(b)

During the quarter ended March 31, 2024, and the year ended December 31, 2023 a total amount of nill and $242,538 (which were converted into 8,634,616 shares of common stock), respectively.

SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED

The estimated fair values of the Warrants were measured according to the data as follows:

	As of			As of
	March 31, 2024			December 31, 2023
Expected term		0.21			0.46
Expected average volatility		87	%		224	%
Expected dividend yield		-			-
Risk-free interest rate		4.19	%		5.3	%
Common Stock Market Value	$	0.01024		$	0.015
Warrants rights outstanding measurement input	$	0.01024		$	0.015

SUMMARIZES RELATING TO OUTSTANDING AND EXERCISABLE WARRANTS

The following table summarizes information relating to outstanding and exercisable warrants as of December 31, 2023:

Warrants Outstanding and Exercisable
Number of Warrants		Weighted Average Remaining Contractual life (in years)		Weighted Average Exercise Price		Valuation as of December 31, 2023
	8,334		2.16		0.6	$	23
	32,500		2.61		0.6	$	116
	7,000,000		0.46		0.015	$	203,718

The following table summarizes information relating to outstanding warrants as of March 31, 2024:

Warrants Outstanding
Number of Warrants		Weighted Average Remaining Contractual life (in years)		Weighted Average Exercise Price		Valuation as of March 31, 2024

	7,000,000		0.21		0.01024	$	71,702
	8,334		1.91		0.6	$	23
	32,500		2.36		0.6	$	116

SCHEDULE OF CONVERTIBLE LOANS AMORTIZED COST

The Convertible Loans at amortized cost changes consist of the following as of March 31, 2024 and December 31, 2023:

	March 31, 2024		December 31, 2023
	$000
Opening balance		796		-
Transition from convertible loans measured at fair value to measurement at amortized cost		-		530
Beneficial conversion feature		-		(66	)
Financial expenses related to transition from fair value measurement to amortized cost		-		304
Accrued interest through profit or loss		15		28
Closing balance		811		796

Old CLA [Member]

Class of Warrant or Right [Line Items]

SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED

The estimated fair values of the Convertible loans were measured according to the Monte Carlo Model using the following assumptions:

	As of			As of
	March 31, 2024			December 31, 2023
Expected term (in years)		0.25			0.5
Expected average (Monte Carlo) volatility		83	%		213	%
Expected dividend yield		-			-
Risk-free interest rate		5.46	%		5.26	%
WACC		27	%		27	%

STOCK BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2024

Consultants and Employees [Member]

SCHEDULE OF NUMBER OF OPTIONS

	Three months ended March 31, 2024
	Number of			Weighted average exercise price
	options			in USD

Options outstanding at January 1, 2024		62,349,647		$	0.0007
Options granted during the period		7,900,000		$	0.00373
Options exercised during the period*		(500,000	)	$	0.0001
Options outstanding at the end of period		69,749,647		$	0.00107
Options exercisable at the end of period		25,650,311		$	0.00136

*	A board member exercised his options into shares during the quarter

GENERAL (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (7,570)	$ (6,326)
Stockholders' deficiency	$ (3,153)	$ (2,539)

SCHEDULE OF BALANCE WITH RELATED PARTIES (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Liabilities:
Employees and payroll accruals	$ 267	$ 498
Related party payables	208	129
Short term loans	$ 79	$ 79

SCHEDULE OF TRANSACTION WITH RELATED PARTIES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Related Party Transactions [Abstract]
Salaries and related cost (including stock-based compensation in the amount of $116,000 and $721,000, respectively)	$ 190	$ 1,067

SCHEDULE OF TRANSACTION WITH RELATED PARTIES (Details) (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Related Party Transactions [Abstract]
Shared based compensation	$ 116,000	$ 721,000

RELATED PARTY BALANCES AND TRANSACTIONS (Details Narrative)	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2024 ILS (₪)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 ILS (₪)
Noncontrolling Interest [Member] \| Tanooma Ltd [Member]
Related Party Transaction [Line Items]
Due to related parties current and noncurrent	$ 31,906	₪ 115,725		₪ 115,725
Nexense Technologies LTD [Member]
Related Party Transaction [Line Items]
Related-party transaction rate	5.18%
Nexense Technologies LTD [Member]
Related Party Transaction [Line Items]
Due from related parties			$ 47,623

SCHEDULE OF FAIR VALUE RECURRING BASIS (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Platform Operator, Crypto Asset [Line Items]
Financial liability	$ 72	$ 204
Fair Value, Recurring [Member]
Platform Operator, Crypto Asset [Line Items]
Assets
Convertible Loans at fair value	2,160	1,203
Financial liability	72	204
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member]
Platform Operator, Crypto Asset [Line Items]
Assets
Convertible Loans at fair value
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member]
Platform Operator, Crypto Asset [Line Items]
Assets
Convertible Loans at fair value
Financial liability
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member]
Platform Operator, Crypto Asset [Line Items]
Assets
Convertible Loans at fair value	2,160	1,203
Financial liability	$ 72	$ 204

SCHEDULE OF CONVERTIBLE LOANS AT FAIR VALUE (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Mar. 31, 2024

Dec. 31, 2023

Convertible Loans And Warrants

Opening Balance, (including short term loans from related party which is also convertible)

$ 1,203

$ 2,257

Additional convertible loans

^[1]

153

Conversion of convertible loan

^[2]

(243)

Decrease of notes purchased

(530)

Change in fair value of convertible loans liability

957

(434)

Closing balance

$ 2,160

$ 1,203

[1]	During the quarter ended March 31, 2024, and the year ended December 31, 2023, the Company raised a principal amount of nill and $152,750, respectively.
[2]	During the quarter ended March 31, 2024, and the year ended December 31, 2023 a total amount of nill and $242,538 (which were converted into 8,634,616 shares of common stock), respectively.

SCHEDULE OF CONVERTIBLE LOANS AT FAIR VALUE (Details) (Parenthetical) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Convertible Loans And Warrants
Principal amount		$ 152,750
Converted amount		$ 242,538
Number of shares converted		8,634,616

SCHEDULE OF FAIR VALUES OF WARRANTS AND CONVERTIBLE LOAN ASSUMPTION USED (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Expected term	2 months 15 days	5 months 15 days
Measurement Input, Price Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants rights outstanding measurement input	87	224
Measurement Input, Expected Dividend Rate [Member]
Class of Warrant or Right [Line Items]
Warrants rights outstanding measurement input
Measurement Input, Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants rights outstanding measurement input	4.19	5.3
Measurement Input Common Market Value [Member]
Class of Warrant or Right [Line Items]
Warrants rights outstanding measurement input	0.01024	0.015
Old CLA [Member]
Class of Warrant or Right [Line Items]
Expected term (in years)	3 months	6 months
Expected average (Monte Carlo) volatility	83.00%	213.00%
Expected dividend yield
Risk-free interest rate	5.46%	5.26%
WACC	27.00%	27.00%

SUMMARIZES RELATING TO OUTSTANDING AND EXERCISABLE WARRANTS (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Weighted Average Remaining Contractual life (in years)	2 months 15 days	5 months 15 days
Warrant One [Member]
Warrants Outstanding and Exercisable, Number of Warrants	7,000,000	8,334
Weighted Average Remaining Contractual life (in years)	2 months 15 days	2 years 1 month 28 days
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	$ 0.01024	$ 0.6
Warrants Outstanding and Exercisable, value	$ 71,702	$ 23
Warrant Two [Member]
Warrants Outstanding and Exercisable, Number of Warrants	8,334	32,500
Weighted Average Remaining Contractual life (in years)	1 year 10 months 28 days	2 years 7 months 9 days
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	$ 0.6	$ 0.6
Warrants Outstanding and Exercisable, value	$ 23	$ 116
Warrant Three [Member]
Warrants Outstanding and Exercisable, Number of Warrants	32,500	7,000,000
Weighted Average Remaining Contractual life (in years)	2 years 4 months 9 days	5 months 15 days
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	$ 0.6	$ 0.015
Warrants Outstanding and Exercisable, value	$ 116	$ 203,718

SCHEDULE OF CONVERTIBLE LOANS AMORTIZED COST (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Convertible Loans And Warrants
Opening balance	$ 796
Transition from convertible loans measured at fair value to measurement at amortized cost		530
Beneficial conversion feature		(66)
Financial expenses related to transition from fair value measurement to amortized cost		304
Accrued interest through profit or loss	15	28
Closing balance	$ 811	$ 796

SCHEDULE OF NUMBER OF OPTIONS (Details) - Consultants and Employees [Member]

3 Months Ended

Mar. 31, 2024

$ / shares

Number of options, Outstanding balance | shares

62,349,647

Weighted average exercise price, Outstanding balance | $ / shares

$ 0.0007

Number of options, Granted | shares

7,900,000

Weighted average exercise price, Granted | $ / shares

$ 0.00373

Number of options, Exercised | shares

(500,000)

^[1]

Weighted average exercise price, Exercised | $ / shares

$ 0.0001

^[1]

Number of options, Outstanding balance | shares

69,749,647

Weighted average exercise price, Outstanding balance | $ / shares

$ 0.00107

Number of options, Exercisable balance | shares

25,650,311

Weighted average exercise price, Exercisable balance | $ / shares

$ 0.00136

[1]	A board member exercised his options into shares during the quarter

STOCK BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended
STOCK BASED COMPENSATION (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Share based compensation	$ 172,000	$ 279,000
Chief Financial Officer And Advisor [Member]
Share based compensation	$ 147,000	$ 279,000

SIGNIFICANT EVENTS DURING THE PERIOD (Details Narrative) - USD ($)		3 Months Ended
	Jan. 01, 2024	Mar. 31, 2024
Additional investment received		$ 456,431
Investment shares issued		7,500,000
Consultant [Member]
Stock option granted	2,300,000
Stock option granted, value	$ 34,350
Option vesting description	The Options are vested on a monthly basis, over a period of 30 months as of the commencement date ending June 30, 2026. The options are exercisable at a per share exercise price of $0.01
Share price	$ 0.01
Consultant One [Member]
Stock option granted	600,000
Stock option granted, value	$ 8,961
Option vesting description	The Options are vested on a monthly basis, over a period of 30 months as of the Commencement Date ending June 30, 2026. The Option are exercisable at a per share exercise price of $0.01
Share price	$ 0.01
Consultant Two [Member]
Stock option granted	5,000,000
Stock option granted, value	$ 74,675
Option vesting description	Upon grant, the Options vest on a monthly basis, over a period of 12 months as of the Commencement Date ending December 31, 2024. The Option are exercisable at a per share exercise price of $0.0001.
Share price	$ 0.0001

SUBSEQUENT EVENTS (Details Narrative) - USD ($)			3 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Jul. 01, 2024	May 14, 2024	Mar. 31, 2024	Mar. 31, 2023	Apr. 01, 2024	Dec. 31, 2023
Subsequent Event [Line Items]
Proceeds from issuance of common stock			$ 381,000
Common stock exercise price			$ 0.0001			$ 0.0001
Issuance related to expense			$ 49,492
Stock issuance total expense			$ 197,966
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from issuance of common stock		$ 1,500,000
Adi Shemer [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares issued	6,000,000
Common stock exercise price	$ 0.0001
Adi Shemer [Member] \| Subsequent Event [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Number of shares issued	100,000,000
Officer And Director [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Options outstanding					6,959,692
Common Stock [Member] \| Boris Molchadsky [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Share conversion rate		$ 0.07
Outstanding unpaid compensation		$ 70,000,000
Common Stock [Member] \| Asaf Porat [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Share conversion rate		$ 0.04
Outstanding unpaid compensation		$ 50,000,000
Common Stock [Member] \| Adi Shemer [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Share conversion rate		$ 0.04